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Introduction: The optimal radiation therapy (RT) field design for 
thymomas remains unclear. Here we report the failure patterns in 
stage II–IV thymoma after RT at two tertiary referral centers, classi-
fied according to the new International Thymic Malignancy Interest 
Group definitions.
Methods: We reviewed 156 stage II–IV patients with thymoma 
treated with definitive (n=24) or adjuvant (n=132) RT. All RT was 
delivered without elective nodal irradiation (median dose 5040 cGy). 
Intrathoracic failures were classified as (1) in-field failures (within 
100% isodose line [IDL]), (2) marginal recurrences (<100% and 
≥50% IDL), and (3) out-of-field failures (outside the 50% IDL).
Results: The median follow-up was 61 months. Surgical margins were 
positive in 39%. The median tumor size was 9 cm. The 5-year cumu-
lative incidence of all intrathoracic failures was 24% (n=34). Failures 
occurred within the RT field (n=5), marginally (n=1),  out-of-field 
(n=22), and synchronously in- and out-of-field (n=6). The 5-year 
cumulative incidence of in-field failures was 7%. These were associ-
ated with Masaoka stage and tumor size. Macroscopically positive 
margins were associated with more local failures. Intrathoracic fail-
ures occurred most commonly in the pleural space (n=29) and lymph 
nodes (n=9). Patients with more advanced stage, and those treated 
with intensity-modulated radiation therapy had more intrathoracic 
failures. RT dose and chemotherapy did not impact failure patterns.
Conclusions: Although there were few in-field failures in patients 
who received RT for stage II–IV thymomas, a high rate of  out-of-field 
intrathoracic failures still occurred. Further study is necessary to 
identify treatment approaches that prevent pleural recurrences.
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(J Thorac Oncol. 2014;9: 403–409)
The benefits of radiation therapy (RT) for stage II to IV malignant thymomas remain unclear. In most studies, 
adjuvant radiotherapy does not seem to provide a significant 
survival benefit after complete resection of early-stage thymo-
mas.1–3 Nevertheless, excellent mediastinal and local control 
have been described with the use of adjuvant RT.4,5 However, in 
patients with advanced-stage thymomas multiple population-
based studies have reported improved  disease-specific and 
overall survival (OS) rates with RT.6–9 None of the previously 
published studies on the role of RT have carefully described 
the radiation treatment field design nor used a uniform defini-
tion to describe the patterns of failure in relation to the deliv-
ered radiation dose. RT fields range from RT to the areas of 
gross tumor involvement only to whole mediastinal or even 
low-dose hemithoracic fields.5,10 The ideal design of the radia-
tion field for thymomas therefore remains uncertain. Radiation 
techniques, however, have markedly evolved over the last few 
decades because of increasing conformality of radiation deliv-
ery.11 Furthermore, specific RT definitions and reporting guide-
lines are now available through the work of the International 
Thymic Malignancy Interest Group (ITMIG).12 We therefore 
performed a novel analysis of the failure patterns of stage II to 
IV thymoma after definitive or adjuvant RT according to the 
ITMIG guidelines at two tertiary referral centers.
METHODS AND MATERIALS
We retrospectively reviewed all patients with stage 
II to IV thymomas treated with definitive or adjuvant RT at 
Memorial Sloan-Kettering Cancer Center (n=84) and MD 
Anderson Cancer Center (n=72) between July 1964 and May 
2012. Patients with thymic carcinoma, thymic carcinoids, or 
distant metastatic disease were excluded.
Patient, tumor and treatment characteristics were 
abstracted from the medical records and are presented in 
Tables 1 and 2. Patients’ age, tumor size, and RT dose were 
analyzed as continuous variables. Patients’ sex, race, Masaoka 
stage, and resection margin status, as well as type of RT 
(two-dimensional [2D], three-dimensional conformal radia-
tion therapy [3D-CRT], or intensity-modulated RT [IMRT]) 
were described as categorical variables. 2D techniques were 
predominantly used between 1964 and 1999. Since 2004, 
2D techniques were only used after pneumonectomies. 
3D-CRT using CT-based treatment planning was first used 
in 1991, whereas IMRT was introduced in 2003. At both our 
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institutions, elective nodal RT has not been used for thymic 
malignancies during the last 30 years. Therefore, all patients 
in this study received RT to the tumor bed only without elec-
tive nodal RT. For all postoperative patients, the clinical target 
volume encompassed the surgical resection bed. An additional 
margin of 0.5 to 1 cm was typically added for the planning 
target volume at both institutions. Typically, doses of 50.4 to 
54 Gy were delivered in patients at high risk for microscopic 
residual disease, and doses of 60 Gy were given to patients 
with gross disease. All treatment failures were carefully 
reviewed with respect to their spatial relationships to the RT 
field, and categorized per current ITMIG guidelines as (1) in-
field failures (within the 100% isodose line [IDL]), (2) mar-
ginal failures (<100% and ≥50% IDL), and (3) out-of-field 
failures (outside the 50% IDL).12 Examples for in-field, mar-
ginal, and  out-of-field locoregional recurrences according to 
the new ITMIG guidelines are depicted in Figure 1.
Statistical Methods
Outcome endpoints included local failure, defined as 
any in-field or marginal failure; locoregional failure (LRF), 
defined as any intrathoracic failure including local and out-of-
field failures; distant metastases (DM); and OS. All endpoints 
were calculated from the date of initial pathologic diagnosis. 
For local failure, LRF, and DM, death without a known onco-
logic event was treated as a competing risk. Gray’s test was 
used for categorical variables; the Fine-Gray regression model 
was used for ordinal categorical or continuous variables. All 
variables with a p value less than 0.10 were included in a step-
wise multivariate analysis by using a Fine-Gray regression 
model. The Kaplan–Meier method was used to estimate OS, 
and variables were analyzed using a log-rank test or Cox pro-
portional hazards model for univariate analysis and stepwise 
Cox model for multivariate analysis. Statistical analyses were 
performed by using SAS (SAS Institute Inc., Cary, NC) and R 
package “cmprsk”.
RESULTS
Patient Characteristics
One-hundred and fifty-six patients were identi-
fied as having undergone definitive or adjuvant RT for 
stage II to IV thymoma. Median follow-up was 61 months 
(range, 4–340 months). Patient characteristics are described 
in Table 1. Sex distribution was even, the median age was 
54 years (range, 20–88 years), and 70% of patients were 
white. The majority of patients had stage III or IVA thy-
moma; seven patients had stage IVB thymoma with lymph 
TABLE 1.  Patient and Tumor Characteristics
N = 156 (%)
Sex
  Male 80 51
  Female 76 49
Age at diagnosis
  Median age at diagnosis 54 yrs (range, 20–88)
Race
  White 109 70
  African-American 23 15
  Other 23 15
Masaoka Stage
  II 43 28
  III 74 47
  IVA 32 21
  IVB 7 4
Tumor size [cm]
Median tumor size 9 cm (range, 2–20)
  <5 24 15
  5–9.9 72 46
  10–14.9 48 31
  15+ 6 4
  Unknown 6 4
FIGURE 1.  Examples of in-field, 
marginal, and out-of-field locore-
gional failures.
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node involvement only but no distant metastatic disease. The 
median tumor size at diagnosis was 9 cm (range, 2–20 cm).
Treatment Characteristics
Detailed treatment characteristics are presented in Table 2. 
Twenty-one patients were deemed unresectable and treated 
with definitive RT. For the 135 patients who underwent surgi-
cal resection, 45 underwent thymectomies, 81 required a partial 
lung resection in addition to the thymectomy, and nine patients 
had pneumonectomies. The resection margin was negative in 
71 patients, microscopically or macroscopically positive in 
62 patients (microscopically positive: 39 patients; macroscopi-
cally positive: 17 patients; positive, not otherwise specified: 
6 patients), and detailed margin status information unavailable 
in two patients. All resected patients were treated with postop-
erative RT. Fifty-nine patients were treated with 2D techniques, 
38 with 3D-CRT, and 59 with IMRT. The median dose was 5040 
cGy in 28 fractions (range, 4000–6600 cGy). Chemotherapy, 
typically a combination of cisplatin, adriamycin, and cyclophos-
phamide ± prednisone, was given to 83 patients, preoperatively 
in 71 patients and postoperatively in 12 patients.
Failure Patterns
The 5- and 10-year cumulative incidence of local failures 
within the radiation field was 7% and 9%, respectively, with 
12 patients experiencing local failures. Increasing Masaoka 
stage (hazard ratio [HR], 3.9; p = 0.001) and tumor size (HR, 
1.14; p = 0.001) were significantly associated with local fail-
ures. Stage IV patients had a 10-year incidence of local fail-
ure of 19% compared with 8% in stage III and 0% in stage 
II patients (Fig. 2). In patients who underwent surgical resec-
tion, microscopically (R1 resection) or macroscopically (R2 
resection) positive margins were borderline significant for local 
failures when compared with negative margin status (p=0.06). 
Macroscopically positive versus negative or microscopically 
positive margins were associated with a significantly higher 
risk for local failures on univariate analysis (p=0.005). Surgical 
resection, chemotherapy, RT dose, RT technique, and year of 
diagnosis did not impact the risk for local failures. Multivariate 
analysis was unreliable because of the small number of events.
Locoregional failures including in-field, marginal, and 
out-of-field intrathoracic failures were observed in 34 patients, 
with a 5- and 10-year incidence of 24% and 26%, respectively. 
Five patients had isolated in-field failures, one patient had a 
marginal failure, 22 patients had out-of-field failures, and six 
patients had synchronous in-field and out-of-field failures 
(Fig. 3). The most common site of all intrathoracic failures was 
the pleural space (n = 29). Lymph node recurrence occurred 
in nine patients. The only patient with a marginal failure was a 
 46-year-old woman with stage IVA, World Health Organization 
type B1 thymoma who underwent induction chemotherapy 
with cisplatin/etoposide for four cycles with a partial response. 
At the time of surgical resection, the residual tumor measured 
9.3 cm at greatest diameter and was 80% necrotic. There was 
invasion of the pleura and pericardium, and a complete thy-
mectomy and left upper lobe wedge resection was performed. 
A small area of gross residual disease over the pulmonary 
artery was found to be unresectable (R2 resection).The patient 
was treated with 3D-CRT to a total dose of 5040 cGy in 28 
fractions without any significant toxicity. Fifteen months after 
completion of adjuvant radiation therapy, the patient developed 
multiple pleural masses, including an anterior diaphragmatic 
mass that was located between the 50% and 100% IDL upon 
reconstruction of her treatment field. This mass was therefore 
recorded as a marginal failure. The patient was treated with 
salvage chemotherapy and resection of pleural masses, but 
ultimately developed liver metastases after 5 years and died of 
disease 7 years after completion of RT.
On univariate analysis, increasing Masaoka stage was 
associated with a higher risk for LRF (p=0.002). Macroscopically 
positive margins (R2 versus other, HR 2.00, p=0.06), any posi-
tive margins (R2/R1 versus negative margins, HR 1.89, p= 0.08), 
and tumor size (HR 1.08, p=0.052) were marginally significant. 
The use of IMRT and a more recent year of diagnosis were also 
associated with more frequently observed LRFs. Among 59 
patients treated with 2D techniques, four patients had in-field (all 
tumor bed), zero marginal, six out-of-field, and one synchronous 
in- and  out-of-field failures (all pleural-based). In 38 patients 
treated with 3D-CRT, there were zero in-field, one marginal, five 
 out-of-field, and one synchronous in- and out-of-field failures 
(all pleural). Among 59 patients treated with IMRT, one in-field, 
zero marginal, 11 out-of-field (10 pleural, 1 nodal site), and four 
synchronous in- and out-of-field failures were observed.
On multivariate analysis, Masaoka stage (stage II ver-
sus IV, HR = 0.21, p = 0.005; stage III versus IV, HR = 0.46, 
TABLE 2.  Treatment Characteristics
n (%)
Type of surgery
  Thymectomy 45 29
  Thymectomy + partial lung resection 81 52
  Pneumonectomy 9 6
  Unresectable 21 13
Margin status
  Negative 71 46
  Microscopically positive 39 25
  Macroscopically positive 17 11
  Positive, not otherwise specified 6 4
  Unresectable/not applicable 23 15
Chemotherapy
  Preoperative 71 46
  Postoperative 12 7
  None 73 47
Radiotherapy technique
  Two dimensional 59 38
  3D-CRT 38 24
  IMRT 59 38
Radiotherapy dose
  Median 5040 cGy
  Range
  Interquartile range
4000–6600 cGy
5040–5900 cGy
3D-CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated 
radiotherapy.
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p = 0.04) and IMRT (versus. 2D, HR 3.04; p=0.004) remained 
significantly associated with LRF. Macroscopically positive 
or any positive margins were not significantly associated 
with LRF after adjusting for Masaoka stage and type of 
RT. The 10-year incidence of LRF was 45% for stage IV 
patients compared with 24% for stage III and 13% for stage 
II patients (Fig. 4).
DMs were observed in 14 patients. The 5- and 10-year 
incidence of DM was 5% and 12%, respectively. The most 
common sites of DMs were the bones (n = 5) and the liver 
(n = 4). The only significant factor associated with a lower 
incidence of DMs on univariate analysis was the use of che-
motherapy (p=0.03).
The 5- and 10-year OS for all patients was 85% and 
62%, respectively. Although earlier Masaoka stage, the use 
of surgical resection, and negative/close margin status were 
associated with improved OS on univariate analysis, the only 
factor significant on multivariate analysis was the use of surgi-
cal resection (p = 0.001).
DISCUSSION
Although the role of adjuvant radiation therapy in thy-
momas remains controversial, there is emerging evidence 
from large population-based studies that RT is associated with 
improved disease-specific survival, and in some series OS, 
most clearly in patients with stage III or IVA disease.6–9 At least 
one study even identified an OS benefit in patients with stage 
II disease, but this was not confirmed in other studies.1–3,8,9,13 A 
study of patients with stage II or III thymoma by Curran et al.4 
reported a 5-year mediastinal relapse rate of 0% with adjuvant 
RT in completely resected patients, and 21% with adjuvant 
RT after subtotal resections as the site of first recurrence. This 
compared favorably with a 5-year mediastinal relapse rate of 
53% after surgical resection without adjuvant RT. The authors 
FIGURE 2.  Cumulative incidence of local failure 
stratified by Masaoka stage.
FIGURE 3.  Graphical depiction of intrathoracic 
failure sites.
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point out that those patients with mediastinal relapse had an 
unfavorable outcome, with five of eight patients dying from 
disease progression. This may be because of the critical loca-
tion of the mediastinal tumor bed in close proximity to mul-
tiple critical structures, such as the large vessels, the proximal 
airways, the esophagus, and the heart. Adjuvant RT has there-
fore typically targeted the tumor bed with or without elective 
mediastinal irradiation to prevent mediastinal recurrences.
We and others have previously observed that with increas-
ing stage, the pattern of relapse seems to shift toward more fre-
quent pleural recurrences.5,14–18 In our series of 97 surgically 
managed patients with thymoma, eight pleural recurrences and 
five mediastinal recurrences were identified.14 Ogawa et al.5 
described a low rate of mediastinal recurrences in patients 
treated with postoperative RT (median dose, 40 Gy) after com-
plete resection, particularly when whole mediastinal RT was 
given (0% mediastinal recurrences), and also when postopera-
tive RT was delivered to the tumor bed only (8% mediastinal 
recurrences). However, they observed that 38% of patients with 
pleural invasion experienced  pleural-based recurrences. The 
authors conclude that mediastinal RT was effective in preventing 
mediastinal recurrences, but had little impact on pleural-based 
recurrences in patients with pathologic pleural tumor invasion. 
Similarly, a study by Mangi et al.19 reported a 32% recurrence 
rate in patients with stage III thymoma who were treated with 
surgical resection and postoperative RT. All recurrences were 
either pleural-based or distant. Interestingly, the mean time to 
recurrence was significantly longer in patients receiving RT 
compared with those managed only surgically (40 months ver-
sus 10 months; p = 0.03). However, no survival difference was 
seen in this  single-institution study. A large single-institution 
retrospective study of 179 patients described 20 patients with 
recurrences, of which 16 were pleural implants, two were medi-
astinal, and two were distant recurrences.16 Late recurrences 
beyond 5 years from initial surgery were observed in eight of 
these 20 patients. Tumor recurrences were observed more fre-
quently with advanced stage, World Health Organization histol-
ogy type B3 or C, and tumors of 8 cm or more.
Our observation in the current study of 24% locoregional 
recurrences at 5 years and 26% at 10 years is consistent with the 
published literature. At our institutions, only  involved-field RT 
to the tumor bed alone has been used postoperatively. Patients 
did not receive elective mediastinal or pleural irradiation. It is 
conceivable that a suboptimally designed radiation field might 
lead to an increased risk of recurrences in the resection site or 
the pleural space. However, we only identified one marginal 
failure that might have been prevented by a more generously 
designed radiation field as described above. Because this patient 
had synchronous failures in multiple other pleural sites, better 
local control without this marginal failure would likely not have 
changed the overall outcome of her disease. Most other failures 
occurred either in the radiation field despite surgical resection 
and full-dose RT (n = 5) or distant from the radiation field in the 
pleural space (n = 22). Six patients had synchronous in-field and 
intrathoracic  out-of-field failures. One might argue that lymph 
node recurrences in nine patients would indicate the need for 
more generous mediastinal fields. However, only one patient 
experienced an isolated lymph node failure in the mediastinum 
outside the radiation field. All others occurred either within the 
radiation field or in the setting of multiple synchronous fail-
ures inside and outside the radiation field. We therefore feel that 
the radiation field design at our institutions is justified based on 
these results, and we advocate the continued use of irradiation 
to the tumor bed without elective mediastinal irradiation.
Delineation of radiation fields is based on systematic 
margin expansions around the radiographically identified 
gross tumor volume for unresected thymomas and clinical 
target volumes covering the tumor bed and area at risk for 
microscopic residual disease for resected thymomas. These 
are expanded by a margin to account for tumor motion (inter-
nal target volume) and further by an additional margin to 
account for patient positioning inaccuracies (planning target 
volume). Our typical margins of 0.5 to 1.0 cm from clinical 
target volume to planning target volume were consistent with 
the ITMIG guidelines. Currently, ITMIG recommends a mar-
gin from gross tumor volume to clinical target volume of 0.5 
FIGURE 4.  Cumulative incidence of locore-
gional failure stratified by Masaoka stage.
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to 1.0 cm and from internal target volume to planning target 
volume of an additional 0.5 to 1.0 cm.12 We recommend fol-
lowing these expansions as a guide for future radiation treat-
ments for thymomas to make future analyses more uniform.
Because of the rarity of thymomas, a common limita-
tion of outcome studies in this disease is the long timespan 
examined. Consistent with this, the RT technique over the 
timespan of this multi-institutional patient series has consider-
ably evolved. As recently described by Gomez et al.,11 radia-
tion therapy for thymic malignancies has undergone significant 
improvements in the accuracy of treatment simulation, plan-
ning, and delivery. Although the increased conformality of 
modern radiation techniques may pose a higher risk for mar-
ginal failures, IMRT has also been clearly shown in multiple 
organ sites to result in decreased toxicity and allow escalation 
to higher doses.20,21 By their nature, less conformal techniques 
such as 2D conventional radiation deliver more incidental 
radiation to surrounding mediastinal lymph node stations or 
adjacent tissues compared with CT-based simulation and 3D 
conformal or IMRT techniques. The only marginal failure in 
our study occurred in a patient treated with 3D-CRT, thus sug-
gesting that the currently applied margins at our institutions 
are appropriate for using even more conformal techniques such 
as IMRT. We observed more locoregional recurrences (n=16) 
with the use of IMRT (p = 0.004). However, all but one of these 
LRFs occurred in the pleura far outside the radiation field, for 
example, at the diaphragm or the lateral chest wall, and only 
one patient had a recurrence in the radiation field. The major-
ity of these patients (n = 9) presented with stage IV thymomas. 
Improvements in surgical technique have permitted an increas-
ing use of lung-sparing partial pleurectomy/decortication or 
resection of pleural implants in patients with stage IVA disease 
at presentation. However, these resections are rarely considered 
to have obtained a microscopically negative margin given the 
limitations of the resection. Thus we are of the opinion that the 
higher locoregional recurrence rate represents the higher inher-
ent risk of disease progression in these patients, rather than a 
deficiency of IMRT. It may be that the radiation oncologists 
treated stage IV thymomas more aggressively than in the era 
before IMRT, because IMRT allows at least partial treatment 
of the pleura while sparing the normal lung tissue more effec-
tively than 3D-CRT. These patients would likely not have been 
offered treatment with adjuvant RT at all before the availabil-
ity of IMRT. Although the multivariate analysis is supposed to 
take into account confounding factors, the association of LRFs 
with IMRT is likely false because of the use of 2D techniques 
in advanced patients after more complete resections such as 
pneumonectomies and lack of marginal failures observed with 
IMRT. Last, patients have been followed up more closely with 
frequent imaging studies in more recent years, when IMRT 
has been available, thus potentially explaining an earlier and 
more frequent detection of pleural metastases than previously. 
After all, in-field local control, DMs, and OS were not sig-
nificantly altered based on the RT techniques used, suggesting 
that early radiographic detection of pleural metastases may not 
have a significant impact on the overall prognosis of thymoma 
patients. Nevertheless, the detection of pleural metastases will 
make LRF rates seem higher than in previous eras.
Given the predominant pattern of failure in more 
advanced thymomas being pleural recurrences, new therapies 
are urgently needed for this patient population. A variety of 
therapies with the aim of decreasing the risk of pleural recur-
rences are currently under development. Most of them have 
been developed and tested in malignant pleural mesothelioma. 
These include hyperthermic intraoperative pleural chemo-
therapy,22 photodynamic therapy,23 and adjuvant RT including 
low-dose hemithoracic RT and lung-sparing pleural IMRT.24–26 
Postoperative low-dose hemithoracic RT in addition to RT to 
the mediastinal tumor bed has been used by Sugie et al.10 in 12 
patients. A low dose of 11.2 Gy in seven fractions to the entire 
hemithorax including an intact lung was applied in patients 
with pleural dissemination. Alternatively, a dose of 15 to 16 
Gy in 10 fractions was given after resection of disseminated 
lesions. At 5 years, the pleural control rate was 69% overall. 
In stage IVA patients, the pleural control rate with the use of 
hemithoracic RT was 71% at 3 years as opposed to 49% in 
patients receiving RT to the mediastinum only, but the differ-
ence was not clinically significant. Three patients (25%) expe-
rienced grade 2 or grade 4 radiation pneumonitis. Although 
representative of the first use of entire hemithoracic RT, these 
results are modest at best and were associated with a fairly 
high level of toxicity given the low RT dose, likely because 
of the treatment of the entire hemithorax including the lung.
Pleural IMRT has been developed to a degree of techni-
cal precision such that it can be applied to partial or even whole 
pleural radiation fields in patients with bilateral intact lungs.26 
The use of IMRT allows dose escalation of up to approximately 
50 Gy to the entire pleura without exceeding the radiation limits 
of the normal intact lung. This may lead to improved rates of 
pleural dissemination and lower the risk of radiation pneumo-
nitis. Early results in patients with malignant pleural mesothe-
lioma seem promising with pulmonary toxicity rates of 20% or 
lower.24,25 Long-term results on toxicity and outcomes for these 
approaches are pending and selection criteria for these therapies 
need to be further characterized. Applying such techniques to 
patients with thymoma, however, must be done with caution, as 
these patients have a much better prognosis than patients with 
mesothelioma and thus are at an increased risk of experiencing 
long-term side effects from these aggressive treatments.
CONCLUSIONS
In conclusion, we report the first and largest analysis of 
failure patterns of patients with thymoma after RT according 
to the new ITMIG guidelines. Consistent with the previously 
published literature, we found that advanced Masaoka stage is 
the most important risk factor for local and LRF. Adjuvant RT 
to the tumor bed alone without elective nodal or mediastinal 
irradiation was found to result in high rates of local control 
of 90% or more. Marginal failures were infrequent, indicat-
ing that RT without elective nodal irradiation was appropriate. 
Macroscopically positive margins were associated with higher 
local failure rates, whereas RT dose was not significantly asso-
ciated with local or LRFs. Despite high local control rates, 
pleural recurrences were observed in about a quarter of the 
patients, indicating the need for novel therapies to improve 
intrathoracic pleural disease control.
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